137 related articles for article (PubMed ID: 29057249)
1. Indoleamine 2,3-dioxygenase and survivin peptide vaccine combined with temozolomide in metastatic melanoma.
Nitschke NJ; Bjoern J; Iversen TZ; Andersen MH; Svane IM
Stem Cell Investig; 2017; 4():77. PubMed ID: 29057249
[TBL] [Abstract][Full Text] [Related]
2. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
3. Durable Clinical Responses and Long-Term Follow-Up of Stage III-IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study-A Brief Research Report.
Kjeldsen JW; Iversen TZ; Engell-Noerregaard L; Mellemgaard A; Andersen MH; Svane IM
Front Immunol; 2018; 9():2145. PubMed ID: 30283461
[No Abstract] [Full Text] [Related]
4. Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab.
Bjoern J; Iversen TZ; Nitschke NJ; Andersen MH; Svane IM
Cytotherapy; 2016 Aug; 18(8):1043-1055. PubMed ID: 27378345
[TBL] [Abstract][Full Text] [Related]
5. Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase.
Iversen TZ; Engell-Noerregaard L; Ellebaek E; Andersen R; Larsen SK; Bjoern J; Zeyher C; Gouttefangeas C; Thomsen BM; Holm B; Thor Straten P; Mellemgaard A; Andersen MH; Svane IM
Clin Cancer Res; 2014 Jan; 20(1):221-32. PubMed ID: 24218513
[TBL] [Abstract][Full Text] [Related]
6. Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine.
Block MS; Suman VJ; Nevala WK; Kottschade LA; Creagan ET; Kaur JS; Quevedo JF; McWilliams RR; Markovic SN
Melanoma Res; 2011 Oct; 21(5):438-45. PubMed ID: 21697748
[TBL] [Abstract][Full Text] [Related]
7. Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.
Hanihara M; Kawataki T; Oh-Oka K; Mitsuka K; Nakao A; Kinouchi H
J Neurosurg; 2016 Jun; 124(6):1594-601. PubMed ID: 26636389
[TBL] [Abstract][Full Text] [Related]
8. The targeting of indoleamine 2,3 dioxygenase -mediated immune escape in cancer.
Iversen TZ; Andersen MH; Svane IM
Basic Clin Pharmacol Toxicol; 2015 Jan; 116(1):19-24. PubMed ID: 25207460
[TBL] [Abstract][Full Text] [Related]
9. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
[TBL] [Abstract][Full Text] [Related]
10. PCC0208009 enhances the anti-tumor effects of temozolomide through direct inhibition and transcriptional regulation of indoleamine 2,3-dioxygenase in glioma models.
Sun S; Du G; Xue J; Ma J; Ge M; Wang H; Tian J
Int J Immunopathol Pharmacol; 2018; 32():2058738418787991. PubMed ID: 29993291
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma.
Scheibenbogen C; Schmittel A; Keilholz U; Allgäuer T; Hofmann U; Max R; Thiel E; Schadendorf D
J Immunother; 2000; 23(2):275-81. PubMed ID: 10746554
[TBL] [Abstract][Full Text] [Related]
12. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells.
Slingluff CL; Petroni GR; Yamshchikov GV; Barnd DL; Eastham S; Galavotti H; Patterson JW; Deacon DH; Hibbitts S; Teates D; Neese PY; Grosh WW; Chianese-Bullock KA; Woodson EM; Wiernasz CJ; Merrill P; Gibson J; Ross M; Engelhard VH
J Clin Oncol; 2003 Nov; 21(21):4016-26. PubMed ID: 14581425
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer.
Weihrauch MR; Ansén S; Jurkiewicz E; Geisen C; Xia Z; Anderson KS; Gracien E; Schmidt M; Wittig B; Diehl V; Wolf J; Bohlen H; Nadler LM
Clin Cancer Res; 2005 Aug; 11(16):5993-6001. PubMed ID: 16115944
[TBL] [Abstract][Full Text] [Related]
14. Inter- and intrapatient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironment.
Gide TN; Allanson BM; Menzies AM; Ferguson PM; Madore J; Saw RPM; Thompson JF; Long GV; Wilmott JS; Scolyer RA
Histopathology; 2019 May; 74(6):817-828. PubMed ID: 30589949
[TBL] [Abstract][Full Text] [Related]
15. Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A.
Tanner R; Kakalacheva K; Miller E; Pathan AA; Chalk R; Sander CR; Scriba T; Tameris M; Hawkridge T; Mahomed H; Hussey G; Hanekom W; Checkley A; McShane H; Fletcher HA
BMC Infect Dis; 2014 Dec; 14():660. PubMed ID: 25466778
[TBL] [Abstract][Full Text] [Related]
16. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.
von Mehren M; Arlen P; Gulley J; Rogatko A; Cooper HS; Meropol NJ; Alpaugh RK; Davey M; McLaughlin S; Beard MT; Tsang KY; Schlom J; Weiner LM
Clin Cancer Res; 2001 May; 7(5):1181-91. PubMed ID: 11350882
[TBL] [Abstract][Full Text] [Related]
17. Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction.
; Celis E
Cancer; 2007 Jul; 110(1):203-14. PubMed ID: 17541944
[TBL] [Abstract][Full Text] [Related]
18. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
Markovic SN; Suman VJ; Ingle JN; Kaur JS; Pitot HC; Loprinzi CL; Rao RD; Creagan ET; Pittelkow MR; Allred JB; Nevala WK; Celis E
Am J Clin Oncol; 2006 Aug; 29(4):352-60. PubMed ID: 16891861
[TBL] [Abstract][Full Text] [Related]
19. Diversification of Antitumour Immunity in a Patient with Metastatic Melanoma Treated with Ipilimumab and an IDO-Silenced Dendritic Cell Vaccine.
Sioud M; Nyakas M; Sæbøe-Larssen S; Mobergslien A; Aamdal S; Kvalheim G
Case Rep Med; 2016; 2016():9639585. PubMed ID: 27504122
[TBL] [Abstract][Full Text] [Related]
20. Peptide-specific CD8+ T-cell evolution in vivo: response to peptide vaccination with Melan-A/MART-1.
Jäger E; Höhn H; Necker A; Förster R; Karbach J; Freitag K; Neukirch C; Castelli C; Salter RD; Knuth A; Maeurer MJ
Int J Cancer; 2002 Mar; 98(3):376-88. PubMed ID: 11920589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
